These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37581675)

  • 21. [Role of age, comorbidity and renin- angiotensin-aldosterone system in COVID-19. Effects of ACE inhibitors and angiotensin receptor blockers].
    Mareev YV; Mareev VY
    Kardiologiia; 2020 Apr; 60(4):4-9. PubMed ID: 32394850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of renin-angiotensin-aldosterone system inhibitors on COVID-19.
    Matsuzawa Y; Kimura K; Ogawa H; Tamura K
    Hypertens Res; 2022 Jul; 45(7):1147-1153. PubMed ID: 35581498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week.
    Brojakowska A; Narula J; Shimony R; Bander J
    J Am Coll Cardiol; 2020 Jun; 75(24):3085-3095. PubMed ID: 32305401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Navigating Renin-Angiotensin System Inhibitors in Patients with Declines in eGFR.
    Shulman R; Cohen JB
    J Am Soc Nephrol; 2024 Oct; 35(10):1309-1311. PubMed ID: 39137049
    [No Abstract]   [Full Text] [Related]  

  • 25. Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19.
    Bozkurt B; Kovacs R; Harrington B
    J Card Fail; 2020 May; 26(5):370. PubMed ID: 32439095
    [No Abstract]   [Full Text] [Related]  

  • 26. Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis.
    Guo X; Zhu Y; Hong Y
    Hypertension; 2020 Aug; 76(2):e13-e14. PubMed ID: 32458694
    [No Abstract]   [Full Text] [Related]  

  • 27. Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know?
    Vitiello A; Ferrara F
    Eur J Pharmacol; 2020 Sep; 883():173373. PubMed ID: 32679185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Understanding the renin-angiotensin-aldosterone-SARS-CoV axis: a comprehensive review.
    Ingraham NE; Barakat AG; Reilkoff R; Bezdicek T; Schacker T; Chipman JG; Tignanelli CJ; Puskarich MA
    Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32341103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin-II receptor blockers or angiotensin converting enzyme inhibitors for the treatment of hypertension amid COVID-19 pandemic.
    Kow CS; Hasan SS
    Expert Rev Cardiovasc Ther; 2021 Jan; 19(1):99-100. PubMed ID: 33112190
    [No Abstract]   [Full Text] [Related]  

  • 30. COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure.
    Siniorakis E; Arvanitakis S; Nikolopoulos I; Elkouris M
    mBio; 2020 May; 11(3):. PubMed ID: 32444383
    [No Abstract]   [Full Text] [Related]  

  • 31. Blockers of the renin-angiotensin-aldosterone system: almost, but not yet, an absolute weapon against cardiovascular and renal diseases!
    Waeber B
    J Renin Angiotensin Aldosterone Syst; 2012 Mar; 13(1):216. PubMed ID: 22389390
    [No Abstract]   [Full Text] [Related]  

  • 32. Inhibition of the renin-angiotensin-aldosterone system: how to obtain this.
    Pende A; Montecucco F
    Curr Pharm Des; 2012; 18(7):950-1. PubMed ID: 22283769
    [No Abstract]   [Full Text] [Related]  

  • 33. RAAS Blockade and COVID-19: Mechanistic Modeling of Mas and AT1 Receptor Occupancy as Indicators of Pro-Inflammatory and Anti-Inflammatory Balance.
    Melissa Hallow K; Dave I
    Clin Pharmacol Ther; 2021 Apr; 109(4):1092-1103. PubMed ID: 33506503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The concern about ACE/ARB and COVID-19: Time to hold your horses!
    Pergolizzi JV; Varrassi G; Magnusson P; LeQuang JA; Leopoulou M; Paladini A; Taylor R; Wollmuth C; Breve F;
    J Am Pharm Assoc (2003); 2020; 60(6):e88-e90. PubMed ID: 32747165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating sources of bias in observational studies of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use during COVID-19: beyond confounding.
    Cohen JB; D'Agostino McGowan L; Jensen ET; Rigdon J; South AM
    J Hypertens; 2021 Apr; 39(4):795-805. PubMed ID: 33186321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COVID-19: The heart of the issue.
    Woodward B; Kermali M
    J Card Surg; 2020 Aug; 35(8):2112. PubMed ID: 32542802
    [No Abstract]   [Full Text] [Related]  

  • 37. COVID-19 and renin-angiotensin system modulators: what do we know so far?
    de la Cruz A; Ashraf S; Vittorio TJ; Bella JN
    Expert Rev Cardiovasc Ther; 2020 Nov; 18(11):743-748. PubMed ID: 32842817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ACE2 in the renin-angiotensin system.
    Verano-Braga T; Martins ALV; Motta-Santos D; Campagnole-Santos MJ; Santos RAS
    Clin Sci (Lond); 2020 Dec; 134(23):3063-3078. PubMed ID: 33264412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Should renin-angiotensin system inhibitors be stopped or not before non-cardiac surgery?
    Halvorsen S; Vranckx P; van Diepen S
    Eur Heart J Acute Cardiovasc Care; 2024 Sep; 13(9):670-671. PubMed ID: 39257308
    [No Abstract]   [Full Text] [Related]  

  • 40. How should we modify recommended renin-angiotensin-aldosterone system inhibition when facing the cardiorenal syndrome?
    Sexton DJ
    Circ Heart Fail; 2014 May; 7(3):536. PubMed ID: 24847129
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.